| RNA Polymerase II Regulates Topoisomerase 1 Activity to Favor Efficient Transcription L Baranello, D Wojtowicz, K Cui, BN Devaiah, HJ Chung, KY Chan-Salis, ... Cell 165 (2), 357-371, 2016 | 276 | 2016 |
| Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening GL Lin, KM Wilson, M Ceribelli, BZ Stanton, PJ Woo, S Kreimer, EY Qin, ... Science translational medicine 11 (519), eaaw0064, 2019 | 158 | 2019 |
| Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress A Thomas, N Takahashi, VN Rajapakse, X Zhang, Y Sun, M Ceribelli, ... Cancer cell 39 (4), 566-579. e7, 2021 | 126 | 2021 |
| Targeting the AKT pathway in glioblastoma K McDowell, G Riggins, G Gallia Current Pharmaceutical Design, 2011 | 102 | 2011 |
| Drug repurposing screen for compounds inhibiting the cytopathic effect of SARS-CoV-2 CZ Chen, P Shinn, Z Itkin, RT Eastman, R Bostwick, L Rasmussen, ... Frontiers in Pharmacology 11, 592737, 2021 | 80 | 2021 |
| An OpenData portal to share COVID-19 drug repurposing data in real time KR Brimacombe, T Zhao, RT Eastman, X Hu, K Wang, M Backus, ... bioRxiv, 2020 | 78 | 2020 |
| Targeting ACE2–RBD interaction as a platform for COVID-19 therapeutics: Development and drug-repurposing screen of an AlphaLISA proximity assay QM Hanson, KM Wilson, M Shen, Z Itkin, RT Eastman, P Shinn, MD Hall ACS Pharmacology & Translational Science 3 (6), 1352-1360, 2020 | 76 | 2020 |
| Reduced cortical BDNF expression and aberrant memory in Carf knock-out mice KA McDowell, AN Hutchinson, SJE Wong-Goodrich, MM Presby, D Su, ... The Journal of Neuroscience 30 (22), 7453-7465, 2010 | 64 | 2010 |
| Overcoming adaptive therapy resistance in AML by targeting immune response pathways K Melgar, MM Walker, LQM Jones, LC Bolanos, K Hueneman, ... Science translational medicine 11 (508), eaaw8828, 2019 | 62 | 2019 |
| Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing SarcomaSynergy of PARP and NAMPT … CM Heske, MI Davis, JT Baumgart, K Wilson, MV Gormally, L Chen, ... Clinical Cancer Research 23 (23), 7301-7311, 2017 | 54 | 2017 |
| Augmented efficacy of brentuximab vedotin combined with ruxolitinib and/or Navitoclax in a murine model of human Hodgkin’s lymphoma W Ju, M Zhang, KM Wilson, MN Petrus, RN Bamford, X Zhang, R Guha, ... Proceedings of the National Academy of Sciences 113 (6), 1624-1629, 2016 | 46 | 2016 |
| The transcription factor CaRF limits NMDAR‐dependent transcription in the developing brain MR Lyons, LF Chen, JV Deng, C Finn, AR Pfenning, A Sabhlok, ... Journal of neurochemistry, 2016 | 34 | 2016 |
| Overcoming acquired epigenetic resistance to BTK inhibitors AL Shaffer III, JD Phelan, JQ Wang, DW Huang, GW Wright, M Kasbekar, ... Blood Cancer Discovery 2 (6), 630-647, 2021 | 32 | 2021 |
| Targeting AML-associated FLT3 mutations with a type I kinase inhibitor LQM Jones, K Melgar, L Bolanos, K Hueneman, MM Walker, JK Jiang, ... The Journal of clinical investigation 130 (4), 2017-2023, 2020 | 31 | 2020 |
| Large-scale pharmacological profiling of 3D tumor models of cancer cells LA Mathews Griner, X Zhang, R Guha, C McKnight, IS Goldlust, ... Cell death & disease 7 (12), e2492-e2492, 2016 | 31 | 2016 |
| Establishment and Biological Characterization of a Panel of Glioblastoma Multiforme (GBM) and GBM Variant Oncosphere Cell Lines ZA Binder, KM Wilson, V Salmasi, BA Orr, CG Eberhart, IM Siu, M Lim, ... PLoS One 11 (3), e0150271, 2016 | 24 | 2016 |
| High-throughput screening identifies candidate drugs for the treatment of recurrent respiratory papillomatosis F Alkhilaiwi, S Paul, D Zhou, X Zhang, F Wang, N Palechor-Ceron, ... Papillomavirus Research 8, 100181, 2019 | 23 | 2019 |
| High-Throughput Screening for Drug Combinations P Shinn, L Chen, M Ferrer, Z Itkin, C Klumpp-Thomas, C McKnight, ... Bioinformatics and Drug Discovery, 11-35, 2019 | 19 | 2019 |
| Rigosertib Induces Mitotic Arrest and Apoptosis in RAS-Mutated Rhabdomyosarcoma and NeuroblastomaEfficacy of Rigosertib in Rhabdomyosarcoma and Neuroblastoma JT Kowalczyk, X Wan, ER Hernandez, R Luo, GC Lyons, KM Wilson, ... Molecular cancer therapeutics 20 (2), 307-319, 2021 | 16 | 2021 |
| A landscape of response to drug combinations in non-small cell lung cancer NU Nair, P Greninger, X Zhang, AA Friedman, A Amzallag, E Cortez, ... Nature Communications 14 (1), 3830, 2023 | 15 | 2023 |
Marc FerrerDirector, NIHכתובת אימייל מאומתת בדומיין mail.nih.gov
